Microbiota-Based Biotherapeutic Drug Reduces Recurrent C. difficile Infections
After 6 months following treatment, 90.5% (38 of 42) responders to RBX2660 remained recurrence-free, whereas 85% (17 of 20) patients in the placebo group remained recurrence-free.
Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection
The Efficacy of Bezlotoxumab in the Prevention of Recurrent Clostridium difficile: A Systematic Review - Cureus
Clostridium difficile infection (CDI) is the most common nosocomial infection in hospitals. Despite the fact that CDI has treatment options, recurrence is common after the treatment, recurrence ...
VIDEO: RBX2660 has potential to break the 'cycle of recurrence' for C.diff icile - Healio
CHARLOTTE, N.C. — In a Healio video exclusive, Paul Feuerstadt, MD, FACG, AGAF, highlighted how live microbiota-based products, such as RBX2660, could drastically transform the treatment of recurrent C. difficile infection.“One of the biggest challenges associated with C. difficile infection is recurrence,” Feuerstadt, assistant clinical professor of medicine at the Yale
RBX2660 for Treatment of Recurrent C. difficile Infection (rCDI) - Pharmacy Times
Drs Feuerstadt, Abraham, and Chopra discuss clinical trial data for RBX2660, a live biotherapeutic product, in treatment of recurrent C difficile infection (rCDI), as well as data with RBX2660 that were presented at DDW 2022.
SER-109, CP101, VE303 for Treatment of Recurrent C. difficile Infection (rCDI) - MD Magazine
Drs Abraham and Feuerstadt share recent data with emerging live biotherapeutic products, SER-109, CP101, and VE303, for treatment of recurrent C difficile infection (rCDI).
Clostridium Difficile Infections Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments - Digital Journal
Clostridium Difficile Infections pipeline constitutes 25+ key companies continuously working towards developing 25+ Clostridium Difficile Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. Clostridium Difficile Infections Overview Clostridium Difficile Infections, also known as Clostridioides difficile or C. difficile is a type of bacteria that causes […]
RBX2660 C Difficile Efficacy Further Demonstrated in Phase 3 Open-Label Study - MD Magazine
RBX2660 reduced clostridioides difficile infection recurrence at 8 weeks, with a sustained clinical response through 6 months, in an open-label phase 3 cohort of patients representative of real-world clinical practice.
Oral SER-109 Effectively Prevents C Difficile Recurrences in Open-Label Study - MD Magazine
Antibiotics followed by oral SER-109 demonstrated a low rate of recurrent clostridioides difficile infection through week 8, regardless of the number of prior episodes.
FDA PDUFA Date Set for C diff Drug, SER-109 - Contagionlive.com
The US FDA has accepted a Biologics License Application (BLA) for Seres Therapeutics' SER-109, and set a Prescription Drug User Fee Act (PDUFA) action date of April 26, 2023.
#idweek2022 #idtwitter clinical trials in bacterial dz that may change your practice @julie_justo #CDI #FMT #microbiota #idmeded #meded pic.twitter.com/Ok8xExcivY— Saira Butt (@SAIRABT) October 23, 2022
Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection — Finch Therapeutics
SOMERVILLE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs,
Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection
SOMERVILLE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage...
Seres Therapeutics Presents SER-109 ECOSPOR IV Study Data at IDWeek and American College of Gastroenterology (ACG) 2022 Annual Meetings - Yahoo Finance
CAMBRIDGE, Mass., October 23, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announces the presentation of safety and efficacy data from its open-label Phase 3 ECOSPOR IV extension study evaluating investigational oral microbiome therapeutic SER-109 for the prevention of rCDI at the IDWeek 2022 and American College of Gastroenterology (ACG) 2022 Annual Meetings. Among the ECOSPOR IV study participants, many of whom have multiple comorbidities, SER-109 w
Seres Therapeutics’ ECOSPOR III Study Data on SER-109 Published in Journal of the American Medical Association - Yahoo Finance
CAMBRIDGE, Mass., October 19, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication of Phase 3 clinical data in the Journal of the American Medical Association (JAMA), highlighting that the clinical benefits of investigational therapeutic SER-109 for preventing recurrent C. difficile infection (rCDI) were apparent as early as two weeks post-treatment and sustained for at least 24 weeks.
Clostridium Difficile Infections Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments - Digital Journal
Clostridium Difficile Infections pipeline constitutes 25+ key companies continuously working towards developing 25+ Clostridium Difficile Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. Clostridium Difficile Infections Overview Clostridium Difficile Infections, also known as Clostridioides difficile or C. difficile is a type of bacteria that causes […]
Tomorrow at 8:40 AM ET, Acurx Pharmaceuticals' will present a poster on Ibezapolstat, the Company's investigative therapy designed to treat patients with #CDiff at @IDWeek2022. For details: https://t.co/khD0p15Pme #IDWeek2022
Tomorrow at 8:40 AM ET, Acurx Pharmaceuticals' will present a poster on Ibezapolstat, the Company's investigative therapy designed to treat patients with #CDiff at @IDWeek2022. For details: https://t.co/khD0p15Pme #IDWeek2022— Antimicrobials Working Group (@AWG_News) October 19, 2022
2022 microbiome market trends report microbiome therapeutics market has advanced to phase 3 with seres therapeutics ser 109 and rebiotix rbx 2660 for recurrent c
Investigational Biotherapeutic Effective Against C. difficile. Up to 24 Months
The investigational microbiota-based live biotherapeutic, which was endorsed by the FDA's Vaccines and Related Biological Products Advisory Committee at the end of ...
The clinical evidence for postbiotics as microbial therapeutics
An optimally operating microbiome supports protective, metabolic, and immune functions, but disruptions produce metabolites and toxins which can be involved in many conditions. Probiotics have the ...
Investigational Biotherapeutic Effective Against C. difficile Up to 24 Months
The investigational microbiota-based live biotherapeutic, which was endorsed by the FDA's Vaccines and Related Biological Products Advisory Committee at the end of ...
.@SeresTX's microbiome therapeutics represent an entirely new class of potential medicines with promise across a wide range of diseases including #CDiff, ulcerative colitis, #AMR infections & GvHD and metastatic #melanoma. Read more: https://t.co/5eSOyNFkV1— MTIG (@MTIG_News) October 13, 2022
Summit Therapeutics to Present Ri-CoDIFy Trial Results for Microbiome-Sparing Ridinilazole at IDWeek 2022 - GlobeNewswire
Menlo Park, California, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) and its product...
